Focus: Denali Therapeutics is a 5,000+ employee biotech company headquartered in South San Francisco specializing in neurodegenerative disease therapies with proprietary blood-brain barrier crossing antibody technology.
Profile data last refreshed 14h ago · AI intelligence enriched 2mo ago
Stable — net +2 jobs in 30d
5 added, 3 removed. Backfill posture.
Strong science and scale appeal undermined by recent clinical failure, cost restructuring, and early-stage pipeline concentration; suitable for risk-tolerant scientists but flag execution concerns in interviews.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Denali Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Denali Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Transcript : Denali Therapeutics Inc. Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-09-2026 09:45 AM - marketscreener.com
Transcript : Denali Therapeutics Inc. Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-09-2026 09:45 AM marketscreener.com
Denali Therapeutics (DNLI) Institutional Ownership 2026 $DNLI - MarketBeat
Denali Therapeutics (DNLI) Institutional Ownership 2026 $DNLI MarketBeat
Denali Therapeutics (NASDAQ: DNLI) holder to sell shares to cover tax on stock units - Stock Titan
Denali Therapeutics (NASDAQ: DNLI) holder to sell shares to cover tax on stock units Stock Titan
Director Nancy Thornberry plans Denali (NASDAQ: DNLI) stock sale - Stock Titan
Director Nancy Thornberry plans Denali (NASDAQ: DNLI) stock sale Stock Titan
Denali Therapeutics (NASDAQ: DNLI) exec plans 2,768-share Rule 144 sale - Stock Titan
Denali Therapeutics (NASDAQ: DNLI) exec plans 2,768-share Rule 144 sale Stock Titan
Denali Therapeutics’ brain-crossing drug hits market - Longevity.Technology
Denali Therapeutics’ brain-crossing drug hits market Longevity.Technology
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
Recent restructuring and clinical setback (May 2026 BIIB122 failure) elevate employment stability risk; monitor earnings calls and partnership announcements closely.
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo